Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
NCT01500551 · View on ClinicalTrials.gov ↗
Study Summary
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
Conditions Studied
Interventions
- DRUG Tofacitinib
Study Locations (20)
California
- Loma Linda University Children'S Hospital — Loma Linda
- Loma Linda University Clinical Trials Center — Loma Linda
- Loma Linda University Eye Institute — Loma Linda
- Loma Linda University General Pediatric Clinic - Meridian — Loma Linda
- Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology) — Loma Linda
- Children's Hospital Los Angeles — Los Angeles
- Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology) — San Bernardino
- Rady Children's Hospital Center for Pediatric Clinical Research — San Diego
- Rady Children's Hospital Rheumatology Clinic — San Diego
- Rady Children's Hospital San Diego- Education and Office Building — San Diego
- Rady Children's Hospital San Diego — San Diego
- Rady Children's Research Pharmacy — San Diego
Georgia
- Center for Advanced Pediatrics — Atlanta
- AU Medical Center — Augusta
- Augusta University — Augusta
District of Columbia
- Children's National Medical Center — Washington D.C.
- IDS Pharmacy — Washington D.C.
Arkansas
- Arkansas Children's Hospital — Little Rock
Connecticut
- Connecticut Children's Medical Center — Hartford
Florida
- Nicklaus Children's Hospital — Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2013-03-18 |
| Est. Completion | 2025-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01500551
The ClinicalTrials.gov registry entry for NCT01500551 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Juvenile Idiopathic Arthritis appearing as the primary indexed condition, and to 1 intervention — of which Tofacitinib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01500551 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Georgia, District of Columbia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01500551 about?
NCT01500551 is a clinical study titled "Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis". Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
What is the current status of trial NCT01500551?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2013-03-18. Estimated completion is 2025-02-12.
What conditions does trial NCT01500551 study?
This clinical trial studies the following conditions: Juvenile Idiopathic Arthritis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT01500551?
The interventions under investigation include: Tofacitinib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT01500551?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01500551 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.